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Protocol
AbstrAct
Introduction Fetal growth restriction (FGR) affects 
5%–10% of all pregnancies, contributing to 30%–50% 
of stillbirths. Unfortunately, growth restriction often is 
not detected antenatally. The last weeks of pregnancy 
are critical for preventing stillbirth among babies with 
FGR because there is a pronounced increase in stillbirths 
among growth-restricted fetuses after 37 weeks of 
pregnancy. Here we present a protocol (V.1, 23 May 2016) 
for the RATIO37 trial, which evaluates an integrated 
strategy for accurately selecting at-risk fetuses for delivery 
at term. The protocol is based on the combination of fetal 
biometry and cerebroplacental ratio (CPR). The primary 
objective is to reduce stillbirth rates. The secondary aims 
are to detect low birth weights and adverse perinatal 
outcomes.
Methods and analysis The study is designed as 
multicentre (Spain, Chile, Mexico,Czech Republic and 
Israel), open-label, randomised trial with parallel groups. 
Singleton pregnancies will be invited to participate after 
routine second-trimester ultrasound scan (19+0–22+6 
weeks of gestation), and participants will be randomly 
allocated to receive revealed or concealed CPR evaluation. 
Then, a routine ultrasound and Doppler scan will be 
performed at 36+0–37+6 weeks. Sociodemographic and 
clinical data will be collected at enrolment. Ultrasound and 
Doppler variables will be recorded at 36+0–37+6 weeks 
of pregnancy. Perinatal outcomes will be recorded after 
delivery. Univariate (with estimated effect size and its 95% 
CI) and multivariate (mixed-effects logistic regression) 
comparisons between groups will be performed.
Ethics and dissemination The study will be conducted 
in accordance with the principles of Good Clinical Practice. 
This study was accepted by the Clinical Research Ethics 
Committee of Hospital Clinic Barcelona on 23May 2016. 
Subsequent approval by individual ethical committees and 
competent authorities was granted. The study results will 
be published in peer-reviewed journals and disseminated 
at international conferences.
Trial registration number NCT02907242; pre-results. 
InTroducTIon
Background and rationale
Fetal growth restriction (FGR) is defined 
as a failure to reach the growth potential. 
FGR affects 5%–10% of all pregnancies and 
contributes to 30%–50% of stillbirths.1 In 
most cases, FGR is due to placental insuf-
ficiency.2 Population-based studies have 
endorsed not only the linkage between FGR 
and increased risk of mortality and morbidity 
in the perinatal period, but the risk of 
delayed consequences into childhood and 
adulthood.3–5 Therefore, antenatal identifica-
tion of FGR is crucial to optimise the timing 
of delivery and to reduce perinatal risks.5 6 
Unfortunately, growth restriction often is not 
detected antenatal. During routine clinical 
practice, as many as 75% of babies at risk 
for FGR are not recognised before delivery.7 
Notably, the gestational age at birth of FGR-re-
lated but undetected stillbirths is 280 days, 
Strengths and limitations of this study
 ► This is the first randomised study examining the 
impact on perinatal heath of evaluating the fetal 
cerebroplacental ratio to select patients for labour 
induction.
 ► The sample size is powered to detect clinically 
relevant reductions in hard adverse perinatal events, 
including perinatal death.
 ► The generalisability of this study is supported by 
the multicentre design, covering medium-income to 
high-income settings.
 ► The nature of the intervention makes it impossible to 
blind participants,
 ► Follow-up of the offspring is limited to the neonatal 
period.
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while it is 270 days in detected cases.5 This indicates that 
the last weeks of pregnancy are critical to prevent stillbirth 
for FGR babies. This conclusion is further supported by 
large-scale studies showing that there is a pronounced 
increase in stillbirths among small fetuses after 37 weeks 
of pregnancy.8
Antenatal screening for small for gestational age/FGr
The first step to detect FGR due to placental insufficiency 
is to detect fetuses at risk for small for gestational age 
(SGA). SGA at birth is defined as birth weight below the 
10th percentile for local standards at each study site. The 
typical third trimester strategy to monitor growth involves 
fetal weight measurement. However, most SGA infants are 
not detected in low-risk populations using this strategy.9 
Although the use of strictly defined methodology and 
maternal-customised standards could potentially improve 
fetal weight measurement,10 evidence supporting its 
use is lacking. Routine third trimester ultrasound scan 
performs better than selective scans based on risk factors 
(evidence level IB).11 In addition, one random controlled 
trial reported that a 36-week scan provided better predic-
tion of SGA at birth than a 32-week scan.12 The risk of 
delaying the scan after 36 weeks is that the stillbirth rate 
increases among SGA babies after 37 weeks.8
Once SGA is suspected, healthcare providers should 
determine whether the fetus has constitutional small-
ness or true FGR using one of several possible strategies. 
The rationale of customisation adjusts for fetal growth 
standards with respect to maternal characteristics that 
influence fetal size, such as parity, maternal weight and 
height and ethnicity. By determining an individualised 
growth potential for each fetus, constitutional smallness 
could be differentiated from FGR. Although this concept 
has been shown to be useful in neonates to predict 
adverse neonatal outcomes,13 customised standards have 
not been shown to improve the detection of placental 
insufficiency in fetuses.14
Fetuses destined to have an adverse outcome have a 
slower growth rate than those with normal outcomes.15 
In SGA babies, some studies have found that growth 
rate performs better as a marker than other fetal and 
maternal parameters.11 16 However, there is controversy 
regarding the best methodology to use for longitudinal 
growth measurement, and multiple strategies have been 
used including conditional assessment, individualised 
longitudinal growth, growth rates and growth trajecto-
ries. Another limitation of longitudinal growth is that 
assessments with intervals <3 weeks are prone to result 
in a large proportion of false positives.17 This problem is 
critical when SGA is diagnosed near term because there 
is not enough time remaining to properly assess longitu-
dinal growth.
In early-intrauterine growth restriction, Doppler assess-
ment of the umbilical artery (UA) can reduce perinatal 
mortality and morbidity,18 and is a standard of care in 
fetal monitoring. By contrast, in late SGA, the UA does 
not accurately reflect placental insufficiency.19 Under 
hypoxic conditions, the fetus redistributes its flow towards 
the brain, a phenomenon called brain sparing. This is 
reflected in the middle cerebral artery (MCA) flow, which 
shows decreased pulsatility during Doppler evaluation. A 
proportion of late SGA babies develop abnormal MCA 
and, in a more pronounced way, abnormal cerebropla-
cental ratio (CPR),20 which is the ratio between MCA and 
UA pulsatility index (PI). The evidence suggests that SGA 
babies with abnormal CPR have a 10-fold increased risk 
of adverse outcome,21 which indicates that CPR is a useful 
marker to differentiate constitutional smallness from late 
FGR.
Management and delivery of late-SGA babies
A random controlled trial shows that systematic induction 
of late-SGA babies at 37–38 weeks does not improve peri-
natal and neurodevelopmental outcomes.22 23 However, 
induction at this gestational age does not worsen neonatal 
outcomes and may be more cost-effective than later induc-
tion; therefore, most guidelines recommend delivery of 
SGA babies at risk of placental insufficiency (growth-re-
stricted babies) after 37–38 weeks, which prevents those 
rare but devastating cases of stillbirth that occur during 
the last weeks of pregnancy. There is consensus that 
abnormal CPR is a defining criterion for FGR in SGA 
babies.24
only some FGr babies are small
It is biologically implausible that all cases of placental 
insufficiency occurred in babies with birth weights below 
the 10th percentile. In fact, perinatal mortality remains 
higher in babies between the 10th and the 50th percen-
tile of birth weight,25 suggesting that a proportion of cases 
of placental insufficiency exhibit growth within normal 
ranges. There is evidence showing that normally growing 
babies with abnormal CPR have a higher frequency of 
placental insufficiency as determined by abnormal uterine 
artery Doppler,26 which may impair their neurobehaviour 
at birth.27 Recent work shows that CPR is associated with 
perinatal mortality, independently of birth weight.28 
Finally, there is evidence that abnormal CPR before birth 
is associated with the occurrence of fetal distress during 
labour,29 supporting the concept that CPR reflects latent 
placental insufficiency.
Justification for the study
Although fetal size and CPR independently correlate with 
adverse perinatal outcome, it has not been determined 
whether a strategy of labour induction based on these 
parameters has the potential to prevent stillbirths. It is 
necessary to obtain evidence in support of this hypothesis 
before recommending the widespread use of this strategy.
HypoTHeSIS
A proportion of fetuses with normal growth (as defined 
per current standards) has placental insufficiency and 
restricted growth potential. These fetuses exhibit biophys-
ical changes that can be detected by abnormal CPR. The 
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combination of abnormal CPR with fetal biometry to 
detect fetuses affected by FGR could identify the group 
of at-risk babies. Labour induction at term may prevent 
adverse outcomes for these babies.
oBJecTIveS
primary objective
The primary objective is to determine whether the addi-
tion of CPR Doppler evaluation to the standard ultrasound 
biometrical measurements can reduce perinatal mortality 
by efficiently selecting women for labour induction.
Secondary objectives
i. to determine whether the addition of CPR Doppler 
evaluation to the standard ultrasound biometrical 
measurements decreases mild and severe adverse 
perinatal outcomes after labour induction;
ii. to determine whether the addition of CPR Doppler 
evaluation to the standard ultrasound biometrical 
measurements decreases neurological morbidity 
after labour induction;
iii. to determine whether the addition of CPR Doppler 
evaluation to the standard ultrasound biometrical 
measurements decreases non-neurological 
morbidity (defined as prolonged neonatal 
intensive care unit (NICU) stay without criteria of 
neurological morbidity) after labour induction;
iv. to evaluate the predictive capacity of an integrated 
strategy based on the combination of fetal 
biometries and CPR at 36–37 weeks to detect 
prenatal low birth weight.
MeTHodS
Study setting
The study will be conducted within academic hospitals 
with specialist experience in managing FGR, in Spain 
(Hospital Clinic Barcelona), Chile (Hospital Clinico 
Universitario de Santiago Chile), Mexico (Hospital of 
Querétaro) Czech Republic (Palacky University Hospital 
in Olomouc, Charles University Hospital in Prague) and 
Israel (Lis Hospital for Women, Tel Aviv). Each of these 
hospitals attends >3000 deliveries and performs >10 000 
fetal ultrasounds per year.
Trial design
This is a multicentre, open-label, randomised trial with 
parallel groups. The study design adheres to the SPIRIT 
quality standard criteria for randomised trials.30
eligibility criteria
The following five criteria were used for inclusion in 
the study: (i) viable singleton non-malformed fetus at 
the routine second trimester ultrasound, (ii) available 
first trimester scan (with embryo crown-rump length 
measurement), (iii) absence of adverse medical or 
obstetric history, (iv) maternal age at recruitment>18 years 
and (v) capacity to give informed consent. The following 
three criteria were used for exclusion from the study: (i) 
abnormal karyotype, (ii) structural abnormalities and 
(iii) congenital infections.
exclusion criteria
Women with obstetrical complication arising before 
37 weeks (as premature rupture of membranes (PROM)) 
prompting delivery will be excluded.
Intervention
Trial participants will be allocated to revealed or 
concealed third trimester (36–37 weeks) CPR evaluation. 
In the concealed group, management will adhere to the 
current standard for managing SGA pregnancies. In the 
revealed group, CPR data obtained from Doppler evalua-
tion will be integrated into the criteria used for decisions 
regarding labour induction. The flow chart in figure 1 
illustrates the management strategy following interven-
tion.
Figure 1 Flow chart of study intervention and management. CPR, cerebroplacental ratio; EFW, estimated fetal weight. 
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predictive variables
The predictive variables include fetal biometries, amniotic 
fluid, Doppler evaluation, UAPI and MCA PI. The fetal 
biometries include biparietal diameter, head circumfer-
ence, abdominal circumference and femur length. These 
will be measured according to standardised procedures.31 
The Hadlock formula will be used to calculate estimated 
fetal weight, which will qualify for fetal SGA if it is below 
the 10th percentile.32 Amniotic fluid will be measured 
in the deepest vertical pocket (an abnormal value is 
defined as<20 mm). Doppler measures will be obtained 
in the absence of fetal movements and with voluntarily 
suspended maternal breathing. Doppler parameters will 
be measured automatically from three or more consec-
utively similar waveforms, with the angle of insonation 
as close to 0° as possible. UA PI will be measured from 
a free-floating cord loop. MCA PI will be measured in a 
transversal view of the fetal head, at the level of its origin 
from the circle of Willis. The latter two parameters will be 
used to derive the CPR as follows: MCA PI/UA PI. CPR 




The primary outcome will be perinatal mortality from 
inclusion to +28 neonatal days.
Secondary outcomes
Four secondary outcomes will be recorded, including mild 
adverse perinatal outcome, severe neurological morbidity, 
severe non-neurological morbidity and SGA at birth. 
Mild adverse perinatal outcome is defined as any of the 
following: (i) caesarean section for fetal distress (defined 
according local protocols), (ii) 5 min Apgar score<7, (iii) 
neonatal acidosis at birth (UA pH<7.15 and base excess> 
−12 mEq/L) or (iv) admission to the neonatal unit. 
Severe neurological morbidity is defined as any of the 
following: (i) seizure,34 (ii) interventricular haemorrhage 
>grade II,35 (iii) periventricular leukomalacia36 or (iv) 
hypoxia-ischaemia or encephalopathy.34 Severe non-neu-
rological morbidity is defined as any of the following: 
(i) prolonged NICU stay (>10 days) without criteria of 
neurological morbidity, (ii) necrotising enterocolitis,34 
(iii) acute renal failure (serum creatinine>1.5 mg/dL) or 
(iv) cardiac failure (requiring ionotropic agents). SGA at 
birth is defined as birth weight below the 10th percentile 
for local standards at each study site.
participant timeline
Table 1 shows the study timeline.
Sample size
The required sample size was estimated as follows. For a 
3‰ reduction of the stillbirth rate (from 5‰ to 2‰), 
assuming a type I error of 5% and aiming for a power 
of 80%, a total of 11 582 participants (5791 per arm) 
are required. The participating centres attend a total of 
12 000 deliveries per year. Assuming that 50% of women 
are eligible and willing to participate, it is expected that 
the required sample size can be achieved within 2 years.
Allocation
An online service (http://www. randomization. com) was 
used to generate randomised sequences in blocks of 100 
participants. This ensured a balanced distribution within 
the two study arms, stratified for participating site. The 








Close-out 28 days 
after delivery
Timepoint T1 T2 T3
  Eligibility screen X
  Informed consent X
  Allocation 20–24 weeks X
Interventions
  Concealed X
  Revealed X
Assessments
  Sociodemographic data X
  Medical history X
  Prenatal evaluation (ultrasound 
biometries)
X X
  Doppler assessment X
  Amniotic fluid assessment X
  Perinatal outcome X
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allocation sequence will be sequestered internally by a 
Clinical Trials Unit.
At the time of routine second trimester scans and after 
enrolment, recruiting physicians will obtain the alloca-
tion group from a web-based system. Women who decline 
consent for randomisation but authorise the use of their 
medical data will be included in the database. These data 
will be used for external validity testing of the trial. Due to 
the nature of the intervention, it is not possible to blind 
participants, obstetricians or outcome assessors with 
respect to the study group.
data collection
The coordinator at each site will collect sociodemo-
graphic data and first and second trimester ultrasound 
data. Participants will be scheduled for a third trimester 
ultrasound at 36+0 to 37+6 weeks; these data will be used 
to obtain fetal biometric data, measure the amniotic fluid 
volume in the deepest vertical pocket and calculate CPR. 
Perinatal outcomes will be recorded after delivery and 
at +28 days.
Participant data for this study will be anonymised and 
entered into an electronic case report form (e-CRF) 
hosted in a secured website by each site coordinator. 
Logic and range rules operate in the e-CRF to minimise 
errors in entering the information.
data monitoring
An independent Clinical Trial Unit will perform offline 
data auditing every 6 months to check for missing informa-
tion and errors. Umbilical and middle cerebral Doppler 
images will be requested from a random sample of 25 
women every 6 months to check for accuracy according 
the following criteria: (i) location site (UA free-loop and 
proximal portion of the MCA); (ii) size of the Doppler 
spectral gate (equivalent to the vessel diameter); (iii) 
scale velocity of the pulsed Doppler, which should result 
in a waveform height equivalent to at least 2/3 of the 
y-axis; and (iv) automatic calculation of the PI from at 
least three consecutively similar waveforms. The sites will 
be notified of any deviation from the standard recom-
mendations for amendment.
Statistical analysis
Statistical analysis will be based on the originally assigned 
groups (intention-to-treat). A binomial distribution 
model will be used to determine the 95% CI of propor-
tions. Student’s t-test (or non-parametric Mann-Whitney 
U test) and Pearson’s χ2 test or linear-by-linear χ2 test (for 
trends across ordered categories) will be performed for 
univariate between-group comparisons of quantitative or 
qualitative variables, respectively. A mixed-effects logistic 
regression analysis of the incidence of stillbirth with fixed 
effects for allocation group and random effects for the 
study centre will be used. Logistic regression also will be 
used to determine which of the variables have a significant 
contribution for predicting stillbirth, low birth weight and 
adverse perinatal outcome. In these regression models, 
stepwise algorithms will be performed to select variables 
at p-value cut-off of 0.05 for inclusion and 0.1 for exclu-
sion, with tolerance level>0.01. Goodness-of-fit models 
will be assessed by calculating Nagelkerke’s R2 and by 
performing a Hosmer and Lemeshow's test. Performance 
of the models also will be evaluated by constructing 
receiver operating characteristic (ROC) curves. A subanal-
ysis will be carried out in patients undergoing an elective 
caesarean section. ROC curves will be compared pairwise 
using the DeLong procedure. Open-source software (The 
R Foundation for Statistical Computing) will be used for 
all computations and graph construction (R V2.15.1).
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